GnRH antagonists suppress FSH levels to a greater extent than GnRH agonists [33] and their differential effects on FSH levels might explain the differences in CV risk, development of atherosclerotic plaque formation, metabolic syndrome, and insulin resistance [34]. This evidence concerns the gene GNRH1 and metabolic syndrome.